1-20 of 20
Davide Melisi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2495: CCL3 predicts an exceptional response to TGFβ inhibition in pancreatic ductal adenocarcinoma by sustaining a basal-like ecotype enriched in LIF-producing macrophages

Silvia Pietrobono, Monica Bertolini, Veronica De Vita, Enza Scarlato, Federica Fazzini, Fabio Sabbadini, Domenico Mangiameli, Alberto Quinzii, Simona Casalino, Davide Melisi
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2495.
https://doi.org/10.1158/1538-7445.AM2024-2495
Published: 22 March 2024
View articletitled, Abstract 2495: CCL3 predicts an exceptional response to TGFβ inhibition in pancreatic ductal adenocarcinoma by sustaining a basal-like ecotype enriched in LIF-producing macrophages
Journal Articles

Abstract 3814: Molecular background conditioning by temozolomide in neuroendocrine tumors

Elena Trevisani, Anna Reni, Irene Torresan, Alice Rossi, Michele Borghesani, Silvia Nicolini, Claudio Luchini, Luca Landoni, Davide Melisi, Aldo Scarpa, Michele Milella, Andrea Mafficini, Sara Cingarlini
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3814.
https://doi.org/10.1158/1538-7445.AM2024-3814
Published: 22 March 2024
View articletitled, Abstract 3814: Molecular background conditioning by temozolomide in neuroendocrine tumors
Journal Articles

Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma

Silvia Pietrobono, Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli, Veronica De Vita, Federica Fazzini, Giulia Lunardi, Simona Casalino, Enza Scarlato, Valeria Merz, Camilla Zecchetto, Alberto Quinzii, Giusy Di Conza, Michael Lahn, Davide Melisi
Journal: Cancer Research
Cancer Res (2024) 84 (1): 118–132.
https://doi.org/10.1158/0008-5472.CAN-23-0104
Published: 02 January 2024
View articletitled, Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma
Open the PDF for Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract 1064: Targeting stromal autotaxin synergizes with TGF beta inhibition in pancreatic cancer

Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli, Serena Contarelli, Zoë Johnson, Michael M. Lahn, Silvia Pietrobono, Davide Melisi
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1064.
https://doi.org/10.1158/1538-7445.AM2022-1064
Published: 15 June 2022
View articletitled, Abstract 1064: Targeting stromal autotaxin synergizes with TGF beta inhibition in pancreatic cancer
Journal Articles

Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma

Carla Mottini, Hideo Tomihara, Diego Carrella, Alessia Lamolinara, Manuela Iezzi, Justin K. Huang, Carla A. Amoreo, Simonetta Buglioni, Isabella Manni, Frederick S. Robinson, Rosalba Minelli, Ya'an Kang, Jason B. Fleming, Michael P. Kim, Christopher A. Bristow, Daniela Trisciuoglio, Antonella Iuliano, Donatella Del Bufalo, Diego Di Bernardo, Davide Melisi, Giulio F. Draetta, Gennaro Ciliberto, Alessandro Carugo, Luca Cardone
Journal: Cancer Research
Series: Author Choice
Cancer Res (2019) 79 (21): 5612–5625.
https://doi.org/10.1158/0008-5472.CAN-19-0187
Published: 01 November 2019
View articletitled, Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma
Open the PDF for Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS–Dependent Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status

Pietro Paolo Vitiello, Davide Ciardiello, Claudia Cardone, Giulia Martini, Valentina Belli, Nunzia Matrone, Luca Poliero, Carola Borrelli, Pasquale Vitale, Nicoletta Zanaletti, Teresa Troiani, Davide Melisi, Fortunato Ciardiello, Erika Martinelli
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 295.
https://doi.org/10.1158/1538-7445.AM2019-295
Published: 01 July 2019
View articletitled, Abstract 295: Synergism between oxaliplatin or irinotecan with the PARP inhibitor niraparib in a preclinical model of KRAS/BRAF mutated colorectal cancer is associated with MSI status
Journal Articles

Abstract 2627: Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways

Davide Ciardiello, Pietro Paolo Vitiello, Nunzia Matrone, Valentina Belli, Claudia Cardone, Luca Poliero, Carola Borrelli, Gianluca Arrichiello, Giulia Martini, Vincenza Ciaramella, Giusi Barra, Floriana Morgillo, Teresa Troiani, Davide Melisi, Fortunato Ciardiello, Erika Martinelli
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2627.
https://doi.org/10.1158/1538-7445.AM2019-2627
Published: 01 July 2019
View articletitled, Abstract 2627: Inhibition of TGFβ in colorectal cancer cells is associated with a compensatory activation of AXL and p38 MAPK signaling pathways
Journal Articles

Abstract 3339: Modulating TAK1 expression through the inhibition of GSK3 impairs YAP/TAZ oncogenic functions in pancreatic cancer

Raffaela Santoro, Marco Zanotto, Geny Piro, Carmine Carbone, Giampaolo Tortora, Davide Melisi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3339.
https://doi.org/10.1158/1538-7445.AM2018-3339
Published: 01 July 2018
View articletitled, Abstract 3339: Modulating TAK1 expression through the inhibition of GSK3 impairs YAP/TAZ oncogenic functions in pancreatic cancer
Journal Articles

Abstract 3501: Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling

Carmine Carbone, Geny Piro, Raffaela Santoro, Francesca Simionato, Valeria Merz, Camilla Zecchetto, Aldo Scarpa, Giampaolo Tortora, Davide Melisi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3501.
https://doi.org/10.1158/1538-7445.AM2018-3501
Published: 01 July 2018
View articletitled, Abstract 3501: Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling
Journal Articles

Abstract 973: MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity

Geny Piro, Raffaela Santoro, Marco Zanotto, Carmine Carbone, Giampaolo Tortora, Davide Melisi
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 973.
https://doi.org/10.1158/1538-7445.AM2018-973
Published: 01 July 2018
View articletitled, Abstract 973: MEKK3 sustains EMT and stemness in pancreatic cancer by regulating YAP and TAZ transcriptional activity
Journal Articles

Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC)

Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gaël Deplanque, Martin Fuchs, Joerg Trojan, Helmut Oettle, Mark Kozloff, Ann Cleverly, Ivelina Gueorguieva, Durisala Desaiah, Michael M. Lahn, Al Blunt, Karim A. Benhadji, Josep Tabernero
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT068.
https://doi.org/10.1158/1538-7445.AM2016-CT068
Published: 15 July 2016
View articletitled, Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC)
Journal Articles

Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors

Carmine Carbone, Geny Piro, Francesca Simionato, Fotios Loupakis, Chiara Cremolini, Gabriella Fontanini, Federica Di Nicolantonio, Elisa Moratti, Francesca Ligorio, Marco Zanotto, Raffaela Santoro, Maria Mihaela Mina, Aldo Scarpa, Alberto Bardelli, Giampaolo Tortora, Davide Melisi
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3265.
https://doi.org/10.1158/1538-7445.AM2016-3265
Published: 15 July 2016
View articletitled, Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors
Journal Articles

Abstract 2046: Exposure - response (overall survival [OS]) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in a randomized phase 2, double-blind study

Ivelina Gueorguieva, Josep Tabernero, Davide Melisi, Timothy H. Waterhouse, Colin Miles, Durisala Desaiah, Michael M. Lahn, Ann Cleverly, Karim A. Benhadji
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2046.
https://doi.org/10.1158/1538-7445.AM2016-2046
Published: 15 July 2016
View articletitled, Abstract 2046: Exposure - response (overall survival [OS]) analyses of patients with unresectable pancreatic cancer (PC) treated with galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in a randomized phase 2, double-blind study
Journal Articles

Abstract 579: TAK1-regulated expression of BIRC3 is responsible for chemoradiotherapy (CRT) resistance in esophagogastric junction (EGJ) adenocarcinoma

Geny Piro, Simone Giacopuzzi, Maria Bencivenga, Carmine Carbone, Giuseppe Verlato, Melissa Frizziero, Maria Mihaela Mina, Marco Zanotto, Valeria Merz, Giovanni De Manzoni, Giampaolo Tortora, Davide Melisi
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 579.
https://doi.org/10.1158/1538-7445.AM2015-579
Published: 01 August 2015
View articletitled, Abstract 579: TAK1-regulated expression of BIRC3 is responsible for chemoradiotherapy (CRT) resistance in esophagogastric junction (EGJ) adenocarcinoma
Journal Articles

Abstract 3605: Combined inhibition of IL-1, CXCR1/2, and TGFβ signaling pathways modulates in vivo acquired resistance to anti-VEGF treatment

Carmine Carbone, Anna Tamburrino, Geny Piro, Marco Zanotto, Maria Mihaela Mina, Silvia Zanini, Federico Boschi, Aldo Scarpa, Giampaolo Tortora, Davide Melisi
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 3605.
https://doi.org/10.1158/1538-7445.AM2015-3605
Published: 01 August 2015
View articletitled, Abstract 3605: Combined inhibition of IL-1, CXCR1/2, and TGFβ signaling pathways modulates in vivo acquired resistance to anti-VEGF treatment
Journal Articles

Abstract 3287: Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT

Carmine Carbone, Tania Moccia, Cihui Zhu, Genni Paradiso, Michele Simbolo, Alfredo Budillon, Paul J. Chiao, James L. Abbruzzese, Davide Melisi
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3287.
https://doi.org/10.1158/1538-7445.AM2011-3287
Published: 15 April 2011
View articletitled, Abstract 3287: Pro-inflammatory factors secreted by pancreatic cancers with evasive resistance to anti-VEGF treatment contribute to malignant progression by inducing EMT
Journal Articles

Abstract 616: R1507, the human monoclonal antibody targeting the insulin-like growth factor receptor (IGF-1R), in combination with cetuximab, can reverse acquired resistance to cetuximab in pancreatic and colon cancer models

Davide Melisi, Roberta Rosa, Roberto Bianco, Carmine Carbone, Giampaolo Tortora, Alfredo Budillon, James L. Abbruzzese, Paul J. Chiao, Milind Javle
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 616.
https://doi.org/10.1158/1538-7445.AM10-616
Published: 15 April 2010
View articletitled, Abstract 616: R1507, the human monoclonal antibody targeting the insulin-like growth factor receptor (IGF-1R), in combination with cetuximab, can reverse acquired resistance to cetuximab in pancreatic and colon cancer models
Journal Articles

Abstract 615: Novel Toll-like Receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancers

Giampaolo Tortora, Roberta Rosa, Davide Melisi, Roberto Bianco, Teresa Gelardi, Sonia Garofalo, Roberta Marciano, Luigi Formisano, Lucia Nappi, Vincenzo Damiano
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 615.
https://doi.org/10.1158/1538-7445.AM10-615
Published: 15 April 2010
View articletitled, Abstract 615: Novel Toll-like Receptor 9 (TLR9) agonist IMO inhibits tumor growth and cooperates with cetuximab in K-Ras mutant colon and pancreatic cancers
Journal Articles

Abstract #2783: TGF-\#946;- activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) chemosensitization

Davide Melisi, Qianghua Xia, James Abbruzzese, Paul Chiao
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 2783.
Published: 01 May 2009
View articletitled, Abstract #2783: TGF-\#946;- activated kinase 1 (TAK1) is a drugable target for pancreatic cancer (PC) chemosensitization
Journal Articles

The protein kinase C beta antagonist enzastaurin (LY317615.HCL) inhibits cancer cell growth by multiple mechanisms and is active in EGFR inhibitors-resistant cancer cells

Bianco Roberto, Vincenzo Damiano, Teresa Gelardi, Gennaro Daniele, Rosa Caputo, Davide Melisi, Angelo Raffaele Bianco, Michael Lahn, Fortunato Ciardiello, Giampaolo Tortora
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 518.
Published: 15 April 2006
View articletitled, The protein kinase C beta antagonist enzastaurin (LY317615.HCL) inhibits cancer cell growth by multiple mechanisms and is active in EGFR inhibitors-resistant cancer cells